Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases
Hongpeng Huang, Xuetao Wei · 2025
Read Therapeutic potential of CD20/CD3 bispecific antibodies in the treatment of autoimmune diseases by Hongpeng Huang, Xuetao Wei (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11720466.txt.
Description
Hongpeng Huang and Xuetao Wei review a two-target antibody class for autoimmune disease in a paper from this period. Autoimmune diseases arise when immune cells attack the body's own tissues, as in lupus and rheumatoid arthritis. Harmful B cells drive many such diseases, and draining them with anti-CD20 drugs already helps. Bispecific antibodies that bind both CD20 and CD3 go further.
Such drugs have shown strong gains in blood cancers, the authors note. Their B cell killing logic is much the same, so they may improve care in autoimmune disease too. The review sums up recent findings and the case for trials in that setting.
Catalog record
| CREATOR | Hongpeng Huang, Xuetao Wei |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |